| Title | Minimal change disease: an unusual presentation of marginal zone MALT lymphoma. |
| Publication Type | Journal Article |
| Year of Publication | 2016 |
| Authors | Inayat F, Law JK, Myers-Gurevitch PM, Seshan SV, Perlman AS |
| Journal | Clin Nephrol |
| Volume | 85 |
| Issue | 3 |
| Pagination | 184-8 |
| Date Published | 2016 Mar |
| ISSN | 0301-0430 |
| Keywords | Adenocarcinoma, Aged, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic Combined Chemotherapy Protocols, Bendamustine Hydrochloride, Colonic Neoplasms, Diagnosis, Differential, Humans, Lymphoma, B-Cell, Marginal Zone, Male, Neoplasm Recurrence, Local, Neoplasms, Second Primary, Nephrosis, Lipoid, Proteinuria, Rituximab |
| Abstract | Minimal change disease (MCD) in association with low-grade extra-nodal marginal zone B-cell lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT) (MALT lymphoma) is a rare clinicopathologic entity. We report a 68-year-old male who presented with nephrotic range proteinuria as the first manifestation of underlying MZL, confirmed with standard set of investigations. Being a steroid non-responder, he was treated with rituximab demonstrating a marked response with resolution of proteinuria. However, he relapsed after 3 months. Upon relapse, a combination of rituximab and bendamustine (R-Benda) was initiated achieving sustained resolution of proteinuria. No additional treatment was administered and the proteinuria has remained in remission for over a year. |
| DOI | 10.5414/CN108593 |
| Alternate Journal | Clin Nephrol |
| PubMed ID | 26636329 |
Related Faculty:
Surya V. Seshan, M.D.